Jack Bendheim, President and Chief Executive Officer of Phibro Animal Health Corporation, executed a stock sale totaling 72,198 shares for approximately $3.74 million on February 10-11, 2026. The transaction was conducted through an indirect sale method pursuant to a pre-existing Rule 10b5-1 trading plan, a disciplined investment strategy that allows corporate insiders to establish predetermined selling schedules.
The divestment coincided with the animal health company's strong second-quarter 2026 performance, marked by year-over-year increases across revenue, net income, and earnings per share metrics. The positive financial results reflect momentum from Phibro's expanded product portfolio, particularly its medicated feed additive segment, which has demonstrated growth exceeding internal projections.
Phibro's performance gains have been substantially aided by its late 2024 acquisition, which brought over 37 product lines into its portfolio and enhanced its market position in the animal health sector. The combination of organic growth and strategic acquisitions has positioned the company for continued expansion in its core business segments.